H1N1 News and Research

RSS

Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.

It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.

ASU epidemiologist to take close look at factors impacting influenza dynamics within Mexico

Influenza surveillance mechanisms in Mexico were adequate during the fast-spreading H1N1 outbreak in 2009, yet Mexico did not have the infrastructure to quickly identify the emergence of this novel strain, according to an Arizona State University (ASU) epidemiologist.

21 Feb 2010

Quidel acquires Diagnostic Hybrids for $130 million

Quidel Corporation, a leading provider of rapid diagnostic tests, has completed its previously announced acquisition of Diagnostic Hybrids, Inc. for approximately $130 million in cash.

20 Feb 2010

BioCrossroads' Indiana Seed Fund invests $400,000 in Bioscience Vaccines

BioCrossroads' Indiana Seed Fund has invested in Bioscience Vaccines, Inc. to accelerate the development of biologic materials, which may boost the effectiveness of a wide range of life-saving vaccines.

19 Feb 2010

CMAJ study summarizes risk factors for severe outcome among patients admitted to hospital with H1N1

A new study in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/cgi/doi/10.1503/cmaj.091823 of all patients in Canada admitted to hospital for H1N1 in the first five months of the outbreak summarizes the risk factors for a severe outcome (www.cmaj.ca). The H1N1 pandemic presents important learnings for clinicians and researchers and data on severe outcomes can help inform future treatment and prevention guidelines.

19 Feb 2010

Data from Novavax's Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study presented at WHO meeting

Novavax, Inc. today presented to the world's leading pandemic influenza vaccine experts a summary of the recent preliminary safety and immunogenicity data from its Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study in Mexico.

19 Feb 2010

Amerigroup's fourth-quarter revenues rise 18.5%

Amerigroup Corporation today announced that net income for the fourth quarter of 2009 was $40.2 million, or $0.79 per diluted share, versus $35.9 million, or $0.67 per diluted share, for the fourth quarter of 2008. For the year ended December 31, 2009, the Company's net income was $149.3 million, or $2.85 per diluted share.

19 Feb 2010

Sacred Heart Medical Center fined $8,000 for failing to adhere to state and national H1N1 influenza safety standards

On January 29, 2010, Sacred Heart Medical Center was cited and fined $8,000 for failing to adhere to state and national H1N1 influenza safety standards. The Department of Labor and Industries Division of Occupational Safety and Health issued the citation and fine for violation of Center for Disease Control and Occupational Safety and Health Administration guidelines on H1N1 and also for violation of the DOSH Directive on Enforcement Procedures for High or Very High Occupational Exposure Risk to the 2009 H1N1 Influenza.

19 Feb 2010

BioSante Pharmaceuticals' LibiGel clinical update to be presented at 2010 ISSWSH annual meeting

BioSante Pharmaceuticals, Inc., will present a LibiGel clinical update at the 2010 Annual Meeting of the International Society for the Study of Women’s Sexual Health (ISSWSH), being held from February 18-20, 2010 in St. Petersburg, Florida.

19 Feb 2010

WHO recommends H1N1 be added to next year's seasonal flu virus

The WHO is recommending the H1N1 (swine flu) virus be added to the regular flu vaccine for the Northern Hemisphere's 2010-2011 regular flu season, the Associated Press reports (2/18).

19 Feb 2010

West Pharmaceutical Services reports 19.9% growth in consolidated fourth-quarter sales

West Pharmaceutical Services, Inc. today announced its results for the fourth quarter and full year of 2009.

18 Feb 2010

In naming Islamic Conference Envoy, Obama highlights global health, food security efforts

During a video address to the 7th U.S.-Islamic World Forum meeting in Doha, Qatar, on Saturday, President Barack Obama appointed Rashad Hussain, deputy associate White House counsel, to serve as Special Envoy to the Organization of the Islamic Conference (OIC), the Associated Press reports.

17 Feb 2010

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

NanoViricides, Inc. (the "Company"), reports that it has signed a research and development agreement with Dr. Eva Harris’s laboratory at the University of California, Berkeley (UC Berkeley).

17 Feb 2010

CMAJ study: Increased dosage of Tamiflu required in treating H1N1 influenza patients

An increased dosage of Tamiflu (oseltamivir) for patients with critical illness is unlikely to be required in the treatment of pandemic (H1N1) influenza, contrary to current international guidelines, found a new study http://www.cmaj.ca/cgi/doi/10.1503/cmaj.092127 in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

17 Feb 2010

Sinovac Beijing expands production capacity with acquisition of buildings and land use rights in Changping

Sinovac Biotech Ltd. (SVA), a leading China-based vaccine manufacturer, today announced the completion by its subsidiary, Sinovac Beijing, of the acquisition of buildings and land use rights. The total consideration for the purchase is approximately RMB120 million ($17.6 million), which will be financed from working capital. The initial payment of RMB56.5 million ($8.3 million) will be paid before February 20, 2010 and the balance of the purchase price will be paid in three installments within three years.

16 Feb 2010

WHO will meet to decide if H1N1 has peaked

The WHO will convene a meeting of its emergency committee later this month to assess whether H1N1 (swine flu) has peaked, Keiji Fukuda, the special adviser to the WHO's director general for pandemic influenza, said Thursday, Bloomberg reports.

15 Feb 2010

Rate of seasonal flu vaccination doubles national average at Johns Hopkins East Baltimore medical campus

A campaign that makes seasonal flu vaccinations for hospital staff free, convenient, ubiquitous and hard to ignore succeeds fairly well in moving care providers closer to a state of "herd" immunity and protecting patients from possible infection transmitted by health care workers, according to results of a survey at The Johns Hopkins Hospital.

12 Feb 2010

Study: Hospitalizations for H1N1 differ from hospitalizations associated with typical flu

When compared to a typical flu, the H1N1 virus resulted in a higher proportion of patients requiring specialized hospital services - and affected younger people more - according to a new study released today by the Canadian Institute for Health Information (CIHI).

12 Feb 2010

Emory-UGA IPIRC to host symposium on H1N1 virus

The Emory - University of Georgia Influenza Pathogenesis and Immunology Research Center will host a symposium April 18 - 20 at the Emory Conference Center featuring an international roster of speakers.

11 Feb 2010

Simcere Pharmaceutical Group subsidiary receives Chinese SFDA approval for Zanamivir

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that one of its subsidiaries, Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd., has received new drug registration approval from the State Food and Drug Administration ("SFDA") to manufacture and sell Zanamivir, a neuraminidase inhibitor inhalant used in the prevention and treatment of Influenza A and Influenza B. Zanamivir is marketed globally by GlaxoSmithKline under the trade name Relenza.

11 Feb 2010

Majority of parents worry about safety of H1N1 vaccine

Ask any health professional who cares for children and they will tell you: When H1N1 flu hits, it can be very severe. In the last four months of 2009, nearly 240 children died in the United States from H1N1 flu—more than three times as many child deaths as in a typical non-H1N1 flu season.

10 Feb 2010

H1N1 News and Research

ASU epidemiologist to take close look at factors impacting influenza dynamics within Mexico

Quidel acquires Diagnostic Hybrids for $130 million

BioCrossroads' Indiana Seed Fund invests $400,000 in Bioscience Vaccines

CMAJ study summarizes risk factors for severe outcome among patients admitted to hospital with H1N1

Data from Novavax's Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study presented at WHO meeting

Amerigroup's fourth-quarter revenues rise 18.5%

Sacred Heart Medical Center fined $8,000 for failing to adhere to state and national H1N1 influenza safety standards

BioSante Pharmaceuticals' LibiGel clinical update to be presented at 2010 ISSWSH annual meeting

WHO recommends H1N1 be added to next year's seasonal flu virus

West Pharmaceutical Services reports 19.9% growth in consolidated fourth-quarter sales

In naming Islamic Conference Envoy, Obama highlights global health, food security efforts

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

CMAJ study: Increased dosage of Tamiflu required in treating H1N1 influenza patients

Sinovac Beijing expands production capacity with acquisition of buildings and land use rights in Changping

WHO will meet to decide if H1N1 has peaked

Rate of seasonal flu vaccination doubles national average at Johns Hopkins East Baltimore medical campus

Study: Hospitalizations for H1N1 differ from hospitalizations associated with typical flu

Emory-UGA IPIRC to host symposium on H1N1 virus

Simcere Pharmaceutical Group subsidiary receives Chinese SFDA approval for Zanamivir

Majority of parents worry about safety of H1N1 vaccine

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News